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A B S T R A C T
Objective: The aim of the present study was to evaluate the prognostic value of pretreatment plasma
dimerized plasmin fragment D (D-dimer) levels in endometrial carcinoma after adjusting for venous
thromboembolism (VTE).
Study design: The relationships between the following clinical parameters from 110 patients were investi-
gated: age, histological type, the International Federation of Gynecology and Obstetrics (FIGO) stage, tumor
grade, pretreatment plasma D-dimer level, platelet count, ﬁbrinogen, CA19-9, and CEA levels, progression-
free survival (PFS), and overall survival (OS). A survival analysis was performed using the Kaplan–Meier
method, and prognostic factors were assessed using Cox’s proportional hazards regression model.
Results: High pretreatment D-dimer levels were detected in 32% of cases. High D-dimer levels correlated
with an advanced tumor stage, histological type, and tumor grade (P = 0.001, P = 0.021, P = 0.044). A
multivariate analysis identiﬁed high D-dimer levels as an independent prognostic factor for OS
(P = 0.013), whereas the histological type, but not D-dimer levels had independent prognostic value for
PFS (P = 0.225).
Conclusion: High pretreatment D-dimer levels have an impact on prognoses independently of VTE, and
also have potential as markers to predict surgical outcomes in patients with endometrial carcinoma.
Pretreatment D-dimer levels may contribute to the identiﬁcation of high-risk populations for treatment
decisions.
 2016 The Authors. Published by Elsevier Ireland Ltd. This is an open access article under the CC BY-NC-
ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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Cancer is associated with hypercoagulation [1,2]. In the absence
of venous thromboembolism (VTE), the blood coagulant and
precoagulant systems are frequently observed in cancer patients
[3,4]. Plasma D-dimer is generated via the degradation of cross-
linked ﬁbrin resulting from the proteolytic actions of plasmin [5].
High pretreatment D-dimer levels have been identiﬁed as a poor
prognostic factor in several malignancies including lung, pancreas,
prostate, gastric, colorectal, breast, and nasopharyngeal cancers
[6–10]. Among gynecological cancers, pretreatment D-dimer levels
have been identiﬁed as a negative prognostic factor in ovarian* Corresponding author at: Department of Obstetrics and Gynecology, Shimane
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nd/4.0/).andcervical carcinomas. Although high D-dimer levels are often
detected in patients with endometrial carcinoma, their prognostic
role currently remains unknown. High D-dimer levels have also been
identiﬁed as a predictor of VTE in cancer patients. Furthermore,
the prognosis of cancer patients with VTE is more likely to be poor
[11–13]. However, it has not yet been determined whether high
pretreatment D-dimer levels have an impact on prognoses
independently of VTE in patients with endometrial carcinoma.
Therefore, the aim of the present study was to investigate the
prognostic signiﬁcance of high pretreatment D-dimer levels in
endometrial carcinoma.
Materials and methods
Patients
This study was approved by the Ethics Committee of Shimane
University Faculty of Medicine. We enrolled 108 patients witharticle under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-
Table 1
Clinical characteristics of the patient population (n = 108).
Characteristics No. of patients %
Age at diagnosis, yr
<60 51 47
60 57 53
FIGO stage
I, II 74 69
III, IV 34 31
Histology
Endometrioid 96 89
Others 12 11
Grade
G1 53 49
G2, G3 55 51
VTE
No 103 95
Yes 5 5
FIGO, International of Gynecology and Obstetrics.
Table 2
Relationship between clinicopathological parameters and pretreatment plasma D-
dimer levels (1.0 vs. >1.0 mg/ml).
Variables No. of patients Plasma D-dimer,
mg/ml
P
1.0 >1.0
Age at diagnosis, yr 0.311
<60 51 37 14
60 57 37 20
FIGO stage 0.001
I, II 74 58 16
III, IV 34 16 18
Histology 0.021
Endometrioid 96 70 26
Others 12 4 8
Grade 0.044
G1 53 41 12
G2, G3 55 33 22
VTE N/A
No 103 74 29
Yes 5 0 5
FIGO, International of Gynecology and Obstetrics.
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University Faculty of Medicine between January 1997 and
December 2013.
Diagnoses were based on the conventional morphological
examination of sections stained with hematoxylin and eosin
(H&E), and tumors were classiﬁed according to the WHO classiﬁca-
tion. Tumor staging was performed according to the International
Federation of Gynecology and Obstetrics (FIGO) classiﬁcation.
Tumor grade was assessed using the FIGO system and by nuclear
grading. All patients were primarily treated with surgery (total
abdominal hysterectomy, bilateral salpingo-oophorectomy, and
pelvic lymph node dissection) and adjuvant platinum and taxane
chemotherapy. Pelvic lymph node dissection and adjuvant chemo-
therapy were omitted in patients with stage 1a and grade 1 cancers.
Measurement of D-dimer levels
Pretreatment plasma D-dimer levels were measured no more
than 4 weeks prior to surgery. The latex photometric immunoassay
system was utilized and D-dimer levels were measured using LPIA-
ACE D-D dimer II (Mitsubishi Chemical Medicine Corporation,
Tokyo, Japan) as the reagent. Inter-assay variability was <10%.
Primary pretreatment screening for VTE was performed using
precise evaluations of plasma D-dimer levels and clinical signs
such as leg swelling and tenderness along the distribution of deep
veins. A cut-off level of 1.0 mg/ml was used to distinguish between
high and normal results.
Statistical analysis
Statistical analyses were conducted using the SPSS package
(version 19.0 for Windows; SPSS, Chicago, IL, USA). A univariate
analysis was performed with a binomial logistic regression analysis
for ordered categorical variables. The clinical parameters used for
modeling were as follows: the age of patients at diagnosis (<60 vs.
60 yr), FIGO stage (I/II vs. III/IV), histological type (endometrioid vs.
others), tumor grade (G1 vs. G2/3), pretreatment plasma D-dimer
level (1 vs. >1 mg/ml), plasma ﬁbrinogen level (<450 vs. 450 mg/
dl), platelet count (<35 vs. 35  104ml1), CA19-9 level (<37 vs.
37 U/ml), CEA level (<5 vs. 5 ng/ml), and VTE (yes vs. no). The end
points of the analysis were progression-free survival (PFS) and
overall survival (OS). PFS was deﬁned as the time between the
diagnosis and recurrence of disease. Patients without recurrence at
their last follow-up visit were censored. OS was deﬁned as the time
between the diagnosis and death. Patients alive at their last follow-
up visit were censored. Survival data were plotted as Kaplan–Meier
curves, and the signiﬁcance of differences was determined using the
Log-rank test. Variables that were initially entered into the model
included those indicated to be signiﬁcant (P < 0.3) in the univariate
analysis. These variables were hypothesized to potentially affect the
prognosis of patients and were entered into a multivariate analysis.
The multivariate prognostic analysis was performed using Cox’s
proportional hazards model. Data were censored when patients
were lost to the follow-up. All reported P values were two-sided and
P value < 0.05 was considered signiﬁcant.
Results
Patients and clinical features
This study group consisted of 108 patients with endometrial
carcinoma, the clinical and pathological features of whom are
summarized in Table 1. Age ranged from 27 to 87 years (median
60), and was divided into two groups (<60 years (47%), 60 years
(53%)). Eighty-nine percent of patients had endometrioid carcino-
ma. Sixty-nine percent of patients had FIGO stage I/II, while 31%had stage III/IV. Regarding tumor grade, 49% of patients had G1,
while 51% had G2/3. Plasma D-dimer levels were elevated
(>1.0 mg/ml) in 34 out of 108 patients (31%). The platelet count
was elevated (35  104 ml1) in 12% of patients. Fibrinogen levels
were elevated (450 mg/dl) in 21% of patients. CA19-9 levels were
elevated (37 U/ml) in 26% of patients. CEA levels were elevated
(5 ng/ml) in 19% of patients. VTE was observed in 4.6% of patients.
Relationship between clinicopathological parameters and
pretreatment plasma D-dimer levels in patients with endometrial
carcinoma
We assessed the relationships between clinicopathological
parameters and pretreatment plasma D-dimer levels in patients
with endometrial carcinoma using a binomial logistic regression
analysis. As shown in Table 2, the FIGO stage (P = 0.001), histological
type (P = 0.021), and tumor grade (P = 0.044) correlated with plasma
D-dimer levels.
Univariate and multivariate analyses of prognostic factors in patients
with endometrial carcinoma
A univariate analysis was performed using age, histological type,
clinical stage, grade, pretreatment plasma D-dimer level, the platelet
count, ﬁbrinogen level, CA19-9 level, CEA level, and VTE as possible
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(P < 0.001), clinical stage (P = 0.001), grade (P = 0.015), pretreatment
plasma D-dimer level (P < 0.001; Fig. 1A), ﬁbrinogen level (P = 0.142),
CEA level (P = 0.054), and VTE (P < 0.001) as potential predictors of
PFS. A multivariate analysis conﬁrmed that histological type (except
for endometrioid) (hazard ratio [HR] = 0.016; 95% conﬁdence interval
[CI] = 0.001–0.368; P = 0.01) was an independent risk factor for PFS
(Table 3). Pretreatment plasma D-dimer levels were not associated
with PFS in the present study. Univariate and multivariate analyses
were also performed on OS. As shown in Table 4, the univariate
analysis revealed that age (P = 0.257), histological type (P < 0.001),
clinical stage (P = 0.003), grade (P = 0.039), pretreatment plasma
D-dimer level (P < 0.001; Fig. 1B), ﬁbrinogen level (P = 0.041), CA19-9
level (P = 0.297), CEA level (P = 0.002), and VTE (P < 0.001) were
potential predictors of OS. The multivariate analysis showed that the
pretreatment plasma D-dimer level (>1.0 mg/ml) (hazard ratio
[HR] = 19.646: 95% conﬁdence interval [CI] = 1.874–206.001;
P = 0.013) and histological type (except for endometrioid) (hazard
ratio [HR] = 0.081; 95% conﬁdence interval [CI] = 0.011–0.586;
P = 0.013) were independent risk factors for OS (Table 4).Fig. 1. (A and B) Kaplan–Meier estimates of the prognostic impact of high
pretreatment D-dimer levels on (A) progression-free survival and (B) overall
survival in patients with endometrial carcinoma.Discussion
To the best of our knowledge, this is the ﬁrst cohort study to
determine whether high pretreatment D-dimer levels are a
prognostic factor independently of VTE in patients with endome-
trial carcinoma. Although the prognosis of endometrial carcinoma
is generally favorable [14], the prognosis of some patients remains
poor. The relationship between D-dimer levels and tumors has
recently been attracting increasing attention. The activation of
coagulation in cancer has been widely implicated in tumor
progression and thrombosis [15]. Elevated plasma D-dimer levels
have been associated with a poor prognosis in several malignan-
cies, including lung, pancreas, prostate, gastric, colorectal, breast,
and nasopharyngeal cancers [6–10]. Among gynecological cancers,
plasma D-dimer levels were identiﬁed as a prognostic factor
independently of VTE in ovarian cancer only [16]. Although one
study showed that high D-dimer levels were associated with a poor
prognosis in patients with endometrial carcinoma, VTE was not
considered [17]. High D-dimer levels have previously been repor-
ted to predict VTE in cancer [11,18].
In the present study, we attempted to identify inexpensive and
convenient prognostic factors in patients with endometrial
carcinoma. Our results revealed that high pretreatment D-dimer
levels are an independent prognosticator via Cox’s regression
model, which was similar to that of other malignancies. The
mechanism underlying the relationship between D-dimer levels
and prognosis in patients with endometrial carcinoma currently
remains unclear, and may involve abnormalities in the coagulation
cascade.
Tissue factor (TF), which is also known as thromboplastin, is the
key element in the initiation of the extrinsic pathway of the
coagulation cascade and plays important roles in cancer metastasis
and progression. TF, a 47-kDa transmembrane glycoprotein recep-
tor, is located on the surfaces of various cells, including platelets,
leukocytes, ﬁbroblasts, and endothelial cells, as well as in the smooth
muscle cells surrounding vessel walls; however, it is not expressed
in blood cells or in the cells that line blood vessels. In the extrinsic
pathway, TF activates factor VIIa, and the TF-VIIa complex then
activates factor X to produce a ﬁbrin degradation product (D-dimer).
In another pathway, TF upregulates vascular endothelial growth
factor (VEGF) and downregulates the angiogenesis inhibitor
thrombospondin in order to promote angiogenesis [19]. VEGF is
associated with angiogenesis and tumor progression. A previous
study reported a correlation between the expression of TF and that of
VEGF [20]. The expression of TF and VEGF may also be prognostic
biomarkers in patients with cervical carcinoma, similar to D-dimer
levels; therefore, we need to investigate the relationship between
TF/VEGF and D-dimer levels in the future. If the expression of TF and
VEGF are also prognostic biomarkers, D-dimer levels represent the
most inexpensive and convenient marker. Our results suggest that
the inhibition of VEGF is effective for patients with high pretreat-
ment D-dimer levels. Our institution has participated in a clinical
trial administering bevacizumab to patients with recurrent endo-
metrial carcinoma. We are also interested in differences in response
rates between patients with normal D-dimer levels and those with
high D-dimer levels.
The present study detected a discrepancy in the correlation
between pretreatment D-dimer levels with OS and that between
D-dimer levels with PFS. D-dimer levels strongly correlated with
OS, but not with PFS. Shorter PFS is generally considered to be
related to poor chemosensitivity; therefore, our results showing
that pretreatment D-dimer levels might be related to shorter OS,
but not PFS indicate that pretreatment D-dimer levels are related
to tumor aggressiveness, but not chemoresistance. However,
several other factors could bias this observation, such as elevated
VEGF levels, which are also might be related to prognosis.
Table 3
Univariate and multivariate analyses of progression-free prognostic factors.
Factors Patients Univariate analysis Multivariate analysis
Hazard ratio 95% CI P Hazard ratio 95% CI P
Age at diagnosis, y
<60 51 Ref
60 57 2.743 0.885–8.505 0.081 4.229 0.654–27.457 0.131
FIGO stage
I, II 74 Ref
III, IV 34 8.554 2.385–30.679 0.001 1.407 0.203–9.758 0.729
Histology
Endometrioid 96 Ref
Others 12 0.151 0.054–0.426 <0.001 0.016 0.001–0.368 0.01
Grade
G1 53 Ref
G2, G3 55 12.585 1.636–96.809 0.015 N/A N/A N/A
VTE
no 103 Ref
yes 5 10.244 2.850–36.827 <0.001 N/A N/A N/A
Plasma D-dimer, mg/ml
1.0 74 Ref
>1.0 34 8.897 2.894–27.353 <0.001 3.114 0.497–19.52 0.225
Platelet, ml1
<35  104 95 Ref
35  104 13 1.677 0.482–5.840 0.417 – – –
Fibrinogen, mg/dl
<450 85 Ref
450 23 2.108 0.779–5.706 0.142 0.572 0.059–5.525 0.629
CA19-9, U/ml
<37 80 Ref
37 28 1.329 0.462–3.828 0.598 – – –
CEA, ng/ml
<5.0 88 Ref
5.0 20 2.938 0.982–8.790 0.054 0.314 0.016–6.005 0.442
CI, conﬁdence interval; FIGO, International of Gynecology and Obstetrics.
Table 4
Univariate and multivariate analyses of overall prognostic factors.
Factors Patients Univariate analysis Multivariate analysis
Hazard ratio 95% CI P Hazard ratio 95% CI P
Age at diagnosis, y
<60 51 Ref
60 57 1.977 0.608–6.428 0.257 N/A N/A N/A
FIGO stage
I, II 74 Ref
III, IV 34 10.327 2.230–47.825 0.003 2.199 0.645–7.496 0.208
Histology
Endometrioid 96 Ref
Others 12 0.100 0.032–0.311 <0.001 0.081 0.011–0.586 0.013
Grade
G1 53 Ref
G2, G3 55 8.765 1.110–69.193 0.039 N/A N/A N/A
VTE
No 103 Ref
Yes 5 12.976 3.228–52.156 <0.001 N/A N/A N/A
Plasma D-dimer, mg/ml
1.0 74 Ref
>1.0 34 32.454 4.203–250.608 0.001 19.646 1.874–206.011 0.013
Platelet, ml1
<35  104 95 Ref
35  104 13 1.367 0.303–6.174 0.685 – – –
Fibrinogen, mg/dl
<450 85 Ref
450 23 3.125 1.046–9.335 0.041 N/A N/A N/A
CA19-9, U/ml
<37 80 Ref
37 28 1.814 0.593–5.554 0.297 N/A N/A N/A
CEA, ng/ml
<5.0 88 Ref
5.0 20 6.642 2.016–21.880 0.002 N/A N/A N/A
CI indicates conﬁdence interval; FIGO, International of Gynecology and Obstetrics.
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pendent of tumor entity, suggesting that there is possibility D-dimer
could be a surrogate marker for stage and therefore prognosis.
There were some limitations to the present study. This was a
retrospective study. D-dimer levels were only measured once before
the treatment as a routine examination. Since D-dimer levels have
been indicated as a potential clinical biomarker of aggressive tumor
biology, future longitudinal studies with continuous tests on D-
dimer levels during different periods of treatments are needed
in order to clarify the mechanisms responsible and relationship
between D-dimer levels and patient prognoses. Second, this study
had been conducted in a single center with limited sample size.
In conclusion, we herein identiﬁed high pretreatment plasma
D-dimer levels as potential markers to predict surgical outcomes
independently of VTE in patients with endometrial carcinoma.
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